Pharmaceutical

Janssen seeks EMA approval of RYBREVANT for NSCLC

Janssen has filed a Type II extension of indication application with the EMA seeking approval for Rybrevant for NSCLC.

Feb 10, 2024 - 18:00
Janssen seeks EMA approval of RYBREVANT for NSCLC
Janssen has filed a Type II extension of indication application with the EMA seeking approval for Rybrevant for NSCLC.
Read the original article

Tags:

Previous Article

Pharma and biotech concerned about the stability of large CROs, survey finds

Next Article

Boehringer and CBmed partner to develop cancer therapies

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Merck to acquire Prometheus Biosciences, maker of autoimmune drugs, for $10.8 billion

STAT+: Merck to acquire Prometheus Biosciences, maker o...

Apr 17, 2023

Enzalutamide by Pfizer for Peritoneal Cancer: Likelihoo...

Dec 24, 2023

Ipsen gains global rights to Foreseen Biotech’s FS001 ADC

Ipsen gains global rights to Foreseen Biotech’s FS001 ADC

Jul 14, 2024